Drug-resistant Candida glabrata infection in cancer patients. - Wikidata - wikimedia - TriplyDB

Drug-resistant Candida glabrata infection in cancer patients.

Drug-resistant Candida glabrata infection in cancer patients.

http://www.wikidata.org/entity/Q34426755

about

Emerging Threats in Antifungal-Resistant Fungal Pathogens Coping with stress and the emergence of multidrug resistance in fungi Clinical perspectives on echinocandin resistance among Candida species Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014 Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia.In vitro activity of econazole in comparison with three common antifungal agents against clinical Candida strains isolated from superficial infections Study on the comparative activity of echinocandins on murine gut colonization by Candida albicans.Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.Epidemiology and reporting of candidaemia in Belgium: a multi-centre study.Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection Dose escalation studies with caspofungin against Candida glabrata.Antifungal Action of Methylene Blue Involves Mitochondrial Dysfunction and Disruption of Redox and Membrane Homeostasis in C. albicans.Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction.Upregulation of the Adhesin Gene EPA1 Mediated by PDR1 in Candida glabrata Leads to Enhanced Host Colonization.Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia.Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.Mechanisms of echinocandin antifungal drug resistance.Drug resistance mechanisms and their regulation in non-albicans Candida species.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Phenotypic and Molecular Evaluation of Echinocandin Susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis Strains Isolated during 30 Years in Argentina.Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.Antifungal stewardship considerations for adults and pediatrics.Azole Resistance in Candida glabrata.Genetic Drivers of Multidrug Resistance in Candida glabrata.Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin - case study and brief literature review An Avid Imitator.Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.Updated practice guidelines for the diagnosis and management of aspergillosis: challenges and opportunities.Pharmacological Blockade of the Chemokine Receptor CCR1 Protects Mice from Systemic Candidiasis of Hematogenous Origin.T2 Magnetic Resonance for Fungal Diagnosis.Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.Candida spp. airway colonization: A potential risk factor for Acinetobacter baumannii ventilator-associated pneumonia.Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA.

P2860

Q26750816-85B5EB3E-27DE-4EC3-B919-BD81A3E99B2D Q27025256-0B360608-EFDF-4E38-9537-CB20BA890220 Q28082538-3F7216AD-7376-4F50-8948-0FD97CAC15C5 Q28084643-9126683E-8406-486D-9D24-7F332B958C99 Q31032549-9B5D2EFD-EB8C-40FA-9206-3570207B6C12 Q33683476-252679C7-B0F3-4DD6-BAF6-782648B3D426 Q33851255-3A6FA76C-53B6-418D-AB4C-4489007FB403 Q35633233-EE3DDB53-92B2-4D6B-B83C-794361B0C3C4 Q35880078-64048334-200B-41A8-8ADF-C3A24934EACF Q36196229-006376AF-F0EA-42DF-B65A-A91FD8736591 Q36290663-B5B0A1C3-B993-4F85-B815-8410C6D53250 Q36290758-26C7A686-A416-4ACB-A372-D3594CAE0C98 Q36376559-A03334E3-B3BF-4626-BBD4-44F505E3E595 Q36658607-53009D7A-D588-455F-9C75-3750E8434305 Q36883131-B3F39831-11A4-4126-9925-F176605776CB Q36891186-986F96B7-CE0B-4A4A-9DA7-90E8CC63254F Q37029566-20C92F2D-94CA-47BB-8657-9E82341A835A Q37528498-069ADE08-5C5F-4CB9-A363-7828474ED3AC Q37612980-DA0661A9-6371-4F57-A0F2-051E83FDD1F7 Q37720796-73827B43-CFDD-4121-91DD-A8DC3B198860 Q38412398-6522DD8A-4B71-4EAF-8D3D-805ECD2E3C66 Q38550402-8B1297FF-9770-4478-9208-A8BFCB664E73 Q38708362-3914974B-BDCD-4B0A-8443-950FB1848515 Q38711698-B12074A8-1FDF-4506-BA01-4685B64F3368 Q38810300-710765C0-A7E8-4766-BC88-D5CC15D6F36B Q38916677-49759EE4-6433-487C-9486-BAAA9EA9879E Q38944746-CA006F4C-0C98-4DDE-87A9-600960231B84 Q38985818-6D65A7D5-DE85-44BA-B214-010F16A87DEC Q39065051-8C6D8FCF-779D-4A1B-BF29-57368804D892 Q39416431-AAE94EE7-71D5-4F9C-A53D-2EFF0A27E14C Q40119053-3F6387DB-2116-4D9A-850D-0D014ED0F87C Q40169961-29D79C8E-D04D-4FC5-8AC6-35EECE667B37 Q40184271-74083CFA-203D-42B1-86AC-757FE9AB5596 Q40202924-9129C225-1C63-4354-8AB2-1917F4DE9B82 Q40349447-D4BC4F9A-4681-4CFF-B570-0316545747EF Q40403802-01A01FE0-F364-4C75-BDA4-62987B3D1559 Q40454814-BF510BAB-78E0-4E0C-8A36-2B8A5DE32893 Q40738359-826CD78A-EAF6-426C-A0B6-6D6EADB25BC8 Q40746229-755A1BCE-8B97-4295-9932-6DBB91FE0F62 Q40942390-3616BC19-0F7D-4BAF-8463-FCF9002082EC

P2860

Drug-resistant Candida glabrata infection in cancer patients.

http://www.wikidata.org/entity/Q34426755

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Drug-resistant Candida glabrata infection in cancer patients.

@ast

Drug-resistant Candida glabrata infection in cancer patients.

@en

Drug-resistant Candida glabrata infection in cancer patients.

@nl

type

label

Drug-resistant Candida glabrata infection in cancer patients.

@ast

Drug-resistant Candida glabrata infection in cancer patients.

@en

Drug-resistant Candida glabrata infection in cancer patients.

@nl

prefLabel

Drug-resistant Candida glabrata infection in cancer patients.

@ast

Drug-resistant Candida glabrata infection in cancer patients.

@en

Drug-resistant Candida glabrata infection in cancer patients.

@nl

P1433

Q34426755-DEE64473-2115-472D-B858-C6E7A908736A

P1476

Q34426755-58D24278-F9C8-4586-A4DE-2839C9A07E46

P2093

Q34426755-A6CACE8A-3DD7-415E-A78F-8C6FB3799A91

Q34426755-C4431550-8168-48D4-BB95-412D6FC04279

Q34426755-E357D75E-1ED7-44CD-BF37-77E1B1AD4C16

P2860

Q34426755-019EE8D5-95A4-4D5A-B943-76A38D13AB0F

Q34426755-043E9C88-1460-4993-8288-261F3668CACD

Q34426755-073F4CB6-8346-4AF7-BBDD-5F81CA596FCE

Q34426755-14C3BB41-C5D6-4E7F-93F7-184BB54FB8BD

Q34426755-1EEFB7D2-BDD3-4FC1-B6AD-4D67CEB71A64

Q34426755-26C7788B-6126-435E-9B32-007E54542B8C

Q34426755-46173C29-FA3C-4D58-8E35-630147ABC6B3

Q34426755-50638422-8154-467E-B092-69976653B2BE

Q34426755-51972F02-39B5-44FA-BE8E-5596A7A6BBA0

Q34426755-62EE1D50-A535-4A97-8C20-9852DA4DC445

P304

Q34426755-5063CAD8-44BB-40A8-8DC3-E6BE75974C20

P31

Q34426755-B76D70FC-52D7-40FD-80DC-0B03FEBB0527

P356

Q34426755-2B47C933-2BA2-476A-90CA-C022A0D08FF4

P433

Q34426755-35EAA50A-4DA2-41FC-8BB9-917C3E0A3736

P478

Q34426755-3EC1F8B1-D196-4664-B334-9EB4DB0B0A03

P577

Q34426755-A08D74B5-8242-4D0E-ABC1-ECB9CBAF5A70

P5875

Q34426755-71718BC0-AA8C-42E4-A501-ED37C776920D

P698

Q34426755-812AC574-FA4A-4B6E-9A62-C4E26CA59ACE

P921

Q34426755-E7E10D28-E6C7-4973-970A-E29E7787F0FD

Q34426755-EE898B86-0D63-4E56-B994-D3844CA7CA69

P932

Q34426755-B3223EE2-3017-4FF2-AAC9-A63EF62BBCC6

P356

P1433

Emerging Infectious Diseases

P1476

Drug-resistant Candida glabrata infection in cancer patients.

@en

P2093

Dimitrios Farmakiotis

http://www.w3.org/2001/XMLSchema#string

Dimitrios P Kontoyiannis

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Tarrand

http://www.w3.org/2001/XMLSchema#string

P2860

Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata

Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.

Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.

Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection

The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations

P304

1833-1840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID2011.140685

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267731714

http://www.w3.org/2001/XMLSchema#string

P698

25340258

http://www.w3.org/2001/XMLSchema#string

P921

Candida glabrata

P932

4214312

http://www.w3.org/2001/XMLSchema#string